Correlation Between Equillium and ESSA Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Equillium and ESSA Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Equillium and ESSA Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Equillium and ESSA Pharma, you can compare the effects of market volatilities on Equillium and ESSA Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Equillium with a short position of ESSA Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Equillium and ESSA Pharma.

Diversification Opportunities for Equillium and ESSA Pharma

0.57
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Equillium and ESSA is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Equillium and ESSA Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ESSA Pharma and Equillium is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Equillium are associated (or correlated) with ESSA Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ESSA Pharma has no effect on the direction of Equillium i.e., Equillium and ESSA Pharma go up and down completely randomly.

Pair Corralation between Equillium and ESSA Pharma

Allowing for the 90-day total investment horizon Equillium is expected to generate 0.76 times more return on investment than ESSA Pharma. However, Equillium is 1.31 times less risky than ESSA Pharma. It trades about 0.0 of its potential returns per unit of risk. ESSA Pharma is currently generating about -0.12 per unit of risk. If you would invest  87.00  in Equillium on September 13, 2024 and sell it today you would lose (17.00) from holding Equillium or give up 19.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Equillium  vs.  ESSA Pharma

 Performance 
       Timeline  
Equillium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Equillium is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.
ESSA Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ESSA Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Equillium and ESSA Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Equillium and ESSA Pharma

The main advantage of trading using opposite Equillium and ESSA Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Equillium position performs unexpectedly, ESSA Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will offset losses from the drop in ESSA Pharma's long position.
The idea behind Equillium and ESSA Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device